Preview

Современная ревматология

Расширенный поиск

Вопросы безопасности и фармакоэкономики при лечении хронической боли в спине и конечностях

https://doi.org/10.14412/1996-7012-2011-674

Аннотация

Для лечения хронической боли в спине и конечностях широко используются нестероидные противовоспалительные препараты (НПВП), длительный прием которых связан с риском осложнений, особенно со стороны желудочно-кишечного тракта (ЖКТ). Представлен обзор литературы, посвященной побочным эффектам, возникающим при лечении НПВП, обсуждаются вопросы фармакоэкономики при использовании различных НПВП. Отмечается, что применение селективного ингибитора циклооксигеназы 2 мелоксикама (мовалиса) вызывает меньше побочных эффектов со стороны ЖКТ, чем прием стандартных НПВП, при этом снижаются затраты на лечение осложнений со стороны ЖКТ.

Литература

1. <div><p>Elliott A.M., Smith B.H., Penny K.L. et al. The epidemiology of chronic pain in the community. Lancet 1999; 354: 1248-52.</p><p>Moore R.A. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology (Oxford) 2002; 41(Suppl.1): 7-15.</p><p>Emery P. Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Scand J Rheumatol 1996; 105(Suppl.): 5-12.</p><p>Antonov K.I.M., Isacson D.G.L. Prescription and non-prescription analgesic use in Sweden. Ann Pharmacoter 1998; 32: 485-94.</p><p>Blower A.L., Brooks A., Fenn G.C. et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91.</p><p>Moore N., Verschuren X., Montout C. et al. Excess costs related to non-steroidal antiinflammatory drug utilization in general practice. Therapie 2000; 55: 133-6.</p><p>Cockel R. NSAIDs - should every prescription carry a government health warning? Gut 1987; 28: 515-8.</p><p>Fries J.F. NSAID gastropathy: the second most deadly theumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 28(Suppl.): 6-10.</p><p>Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life treatening complications of peptic ulceration. Gut 1987; 28: 527-32.</p><p>Steinfeld S., Bjorke P.A. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. Rheumatology (Oxford) 2002; 41(Suppl.1): 23-7.</p><p>Tramer M.R., Moore R.A., Reynolds D.J.M. et al. Qualitative estimation of rare adverse events which follow a biological pre-gression: a new model applied to chronic NSAID use. Pain 2000; 85: 169-82.</p><p>Singh G. Recent considerations in nonsteroidal anti-inflammatory gastropathy. Am J Med 1998; 105: 31S-38S.</p><p>Moore R.A., Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999; 156: 2321-32.</p><p>Moore R.A., Phillips C.J., Pellissier J.M. et al. Health economics comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ 2001; 4: 1-17.</p><p>Rahme E., Joseph L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti- inflammatory drugs versus acetaminophen. Arthr Rheum 2000; 43: 917-24.</p><p>de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992; 96(Suppl.): 49-53.</p><p>Knill-Jones R.P. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary of article by G. de Pouvourville. Scand J Rheumatol 1992; 96(Suppl.): 59-62.</p><p>Rahme E., Joseph L., Kong S.X. et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001; 52: 185-92.</p><p>Hurley J., Mucha L., Straus W. et al. NSAID and concomitant gastrointestinal drug use among cases and controls in a managed care population. Gastroenterology 2000; 118(Suppl.): A3914.</p><p>Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on non- steroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.</p><p>Cohen Y., Freeman N.L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti- inflammatory drugs: analysis of a population cohort in Israel. The 14th EULAR Congress. Prague, 13-16 June, 2001.</p><p>Kephart G., Sketris I., Smith M. et al. Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Clin Ther 1995; 17: 1159-73.</p><p>Hogan D.B., Campbell N.R. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J 1994; 151: 315-22.</p><p>Singh G., Ramey D.R. Gastrointestinal tract complications on non-steroidal anti-inflammatory dryg treatment in rheumatoid arthritis. Arch Inern Med 1996; 156: 1530-6.</p><p>Moore N., Montout C. Use of gastrointestinal protective agents among patients on nonsteroidal anti-inflammatory drugs in France and prevention of treqtment of adverse GI effects. 12th EULAR Congress. Glasgow, 6-11 June, 1999.</p><p>Caputi A.P., Kong S.X. Concomitant use of gastroprotective agents among users of nonsteroidal anti-inflammatory drugs in Italy. The 14th EULAR Congress. Prague, 13-16 June, 2001.</p><p>Kawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Brit J Rheumatol 1998; 37(9): 937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large- scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Brit J Rheumatol 1998; 37(9): 946-51.</p><p>Chen Y.F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 12: 11.</p><p>Jansen R.B., Capri S., Nuijten M.J.C. Economic evaluation of meloxicam (7,5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. Brit J Med Econom 1997; 11: 9-22.</p><p>Tavakoli M. Modelling Therapeutic Strategies in the Treatment of Osteoarthritis: An Economic Evaluation of Meloxicam Versus Diclofenac and Piroxicam. Pharmacoeconomics 2003; 21(6): 443-54.</p><p>Насонова В.А., Воробьев П.А., Цветкова Е.С. и др. Фармакоэкономический анализ применения двух нестероидных противовоспалительных препаратов в ревматологии. Науч.-практич. ревматол. 2002; 1: 63-8.</p></div><br />


Для цитирования:


Парфенов В.А., Герасимова О.Н., Парфенов В.А., Герасимова О.Н. Вопросы безопасности и фармакоэкономики при лечении хронической боли в спине и конечностях. Современная ревматология. 2011;5(2):77-80. https://doi.org/10.14412/1996-7012-2011-674

For citation:


Parfenov V.A., Gerasimova O.N., Parfenov V.A., Gerasimova O.N. The issues of safety and pharmacoeconomics in the management of chronic pain in the back and limbs. Modern Rheumatology Journal. 2011;5(2):77-80. (In Russ.) https://doi.org/10.14412/1996-7012-2011-674

Просмотров: 847


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)